Alan Cross, PhD
CSO & Chair, SAB
We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
Recognized as one of the world’s most prominent authorities on mood and anxiety disorders, Dr. Jerry Rosenbaum is a Co-Founder of Psy Therapeutics and an active member of its Scientific Advisory Board. Dr. Rosenbaum is steadfast in his commitment to advancing the discovery of novel drugs and diagnostics for psychiatric disorders and is guiding R&D strategy for anxiety treatments across Psy’s pipeline.
Dr. Rosenbaum served as Psychiatrist-in-Chief at Massachusetts General Hospital (MGH) for over 17 years. Under his leadership, the hospital was consistently ranked as the #1 Department of Psychiatry in the United States by U.S. News and World Report, with 60 specialty clinical and research programs and $60 million of annual research spending.
Highlights of Dr. Rosenbaum’s numerous accolades and awards include:
He is currently President and Board member of the American Foundation for Suicide Prevention and co-Chair of Development at MGH. Previously, Dr. Rosenbaum served as President and Board Chair of the Anxiety and Depression Association of America (ADAA) and as past Chair of the Scientific Council. He has served as a Trustee of MGH and the Partners Healthcare System. Dr. Rosenbaum also served as Chair of Executive Committee on Research at MGH, the nation’s largest hospital-based research institution.
Dr. Rosenbaum received his BA from Yale College and MD from Yale University School of Medicine.